BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38042834)

  • 21. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
    Lee SW; Choi J; Kim SU; Lim YS
    Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
    Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
    Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial.
    Yim HJ; Kim IH; Suh SJ; Jung YK; Kim JH; Seo YS; Yeon JE; Kim CW; Kwon SY; Park SH; Lee MS; Um SH; Byun KS
    J Viral Hepat; 2018 Nov; 25(11):1321-1330. PubMed ID: 29772084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.
    Li P; Wang Y; Yu J; Yu J; Tao Q; Zhang J; Lau WY; Zhou W; Huang G
    JAMA Netw Open; 2023 Oct; 6(10):e2340353. PubMed ID: 37906195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
    Jeong S; Shin HP; Kim HI
    Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation.
    Yang J; Chen Y; Sun H; Zhang X; Wang J; Liang Z; Fu B; Zhang T; Yi S; Deng Y; Yang Y
    Infect Agent Cancer; 2023 Jan; 18(1):2. PubMed ID: 36650583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
    Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
    Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
    Choi WM; Choi J; Lim YS
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):246-258.e9. PubMed ID: 32407970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
    Lin CL; Lin YL; Liang KH; Chen LW; Chien CH; Hu CC; Huang TS; Shyu YC; Yeh CT; Chien RN
    Clin Ther; 2022 Mar; 44(3):403-417.e6. PubMed ID: 35469645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
    Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
    Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.
    Kong Q; Yi M; Teng F; Chen Z
    Asian J Surg; 2024 Jan; 47(1):55-62. PubMed ID: 37739894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
    J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
    Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
    Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Su F; Berry K; Ioannou GN
    Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.